Hoʻolālā ʻana i nā Peptide Reagents no nā kumu hoʻohālike pili kanaka: He alakaʻi kuhikuhi a hōʻoia

Pane wikiwiki

Animal models mispredict human biology often enough that the regulatory ground has shifted: a 2024 systematic analysis in PLoS Biology found that only 5% of an…

He aha ke kumu hoʻohālike preclinical e pili ana i ke kanaka

Mea Hana Kūʻai Nui Peptides Kūʻai i nā Peptides ʻO kahi kumu hoʻohālike preclinical pili i ke kanaka ʻo ia ka mea nona nā ʻōlelo wānana e kau ʻia ma nā cell kanaka, ka hoʻolālā kino kanaka a me ka physiology kanaka ma mua o ka extrapolation cross-species. ʻO ka wehewehe ponoʻī a FDA o nā ʻano hana hoʻokokoke hou e uhi ana i "nā ʻano hoʻokolohua hou a me nā hoʻolālā i hoʻohana ʻia e loiloi i ka palekana, ka pono, a me ka maikaʻi o nā lāʻau lapaʻau, mea olaola, a me nā huahana ʻē aʻe i hoʻoponopono ʻia e FDA,” e pili pū ana me nā ʻōnaehana kumu kanaka in vitro a me ka hoʻohālike silico (FDA, Nā Hana Hana Hou, kēia manawa 2026). ʻOi aku ka haiki o kēlā wehewehe ʻana ma mua o ka huaʻōlelo kānāwai i huikau pinepine ʻia: ka FDA Modernization Act 2.0 ua pani ʻia ʻo "nā hoʻokolohua preclinical (me nā hoʻokolohua ma nā holoholona)” me nā hoʻokolohua nonclinical," a me ka wehewehe kānāwai hou o kahi ho'āʻo nonclinical e pili pū ana i "he ho'āʻo nonhuman in vivo" a papa inoa i ka hoʻāʻo holoholona ma waena o nā ʻano e "hiki" ke hoʻokomo ʻia. (Kānāwai kulekele FDA, 2026). ʻAʻole like ka NAM a me ka hoʻāʻo nonclinical, a ua wehe ke kānāwai i kahi koi me ka pāpā ʻole ʻana i nā haʻawina holoholona.

ʻO ka pilina kekahi waiwai o ka hale hana, ʻaʻole wale no ke kumu cell. A 2025 ʻO ka papa kuhikuhi alanui unuhi organ-on-chip e wehewehe i kēia mau ʻōnaehana ma ke ʻano he hui o "organ" (hale hoʻolālā kelepona a me ka hana physiological) a me ka "chip" (microfabricated paepae), a paʻa i ka pili physiological pono i ka hui multiscale, ka launa pū me ka ʻiʻo me ka endothelium vascular e hōʻailona ana i ka parenchymal a me nā keʻena pili., a me nā hōʻailona mechanical e like me ke koʻikoʻi shear fluid, hoʻopaʻapaʻa a me ka hoʻopaʻa ʻana (Organ-on-a-Chip: He Palapala Ala no ka Huli Huli, 2025).

Hoʻolālā ʻana i nā Peptide Reagents no nā kumu hoʻohālike pili kanaka: He alakaʻi kuhikuhi a hōʻoia

ʻO ka hopena kūpono no ka kikoʻī reagent he hiki ke kanaka i loko o kāna mau cell a ʻaʻole naʻe i pili ke kanaka i kāna heluhelu ʻana.. A 2026 ka loiloi ʻana i nā inoa hana organoid hiki ke hoʻololi ʻia, ʻokoʻa spatial a me reagent variability e like me nā palena ʻekolu o ka reproducibility i ka hana organoid (Mai ka moʻomeheu organoid a i ka hana ʻana, 2026). ʻO ka hoʻololi ʻana o ka reagent ka mea hiki i ka palapala kikoʻī ke hoʻokele pololei.

No ke aha e kaupalena ai nā ʻokoʻa ʻokoʻa i ka waiwai wānana

Hoʻokaʻawale nā ​​ʻokoʻa ʻano ʻano i ka waiwai wānana me ka like ʻole, a ʻo nā helu poʻomanaʻo ʻelua i helu pinepine ʻia e ana i nā mea like ʻole. ʻIke ʻia kahi loiloi hoʻopaʻa ʻōnaehana o ka unuhi holoholona-i-kanaka 71% ka hui ʻana o nā mea ʻawaʻawa ma waena o nā ʻano, aka wale no 43% no na rodents a 63% no nā koʻokoʻo ʻole (Unuhi holoholona i kanaka: he loiloi scoping systematic, 2019). Hōʻike ka loiloi like he liʻiliʻi loa nā ratio likelihood inverse no nā ʻīlio, ʻiole, ʻiole, nā lākeke a me nā primates ʻole kanaka, 'o ia ho'i he hopena maika'i 'ole i loko o ia mau 'ano i ka waiwai wānana no ke kanaka, ʻoiai e hiki mai ana nā hopena maikaʻi i loko o ke kanaka. ʻO ka hoʻāʻo holoholona i hōʻike ʻia i ka ikaika e hōʻike ana i ka ʻawaʻawa e hiki mai ana, ʻaʻole hoʻomaʻemaʻe i kahi hui.

Holoholona unuhi holoholona-a-kanaka No nā hana i ho'āʻoʻia e nā holoholona, 50% hiki i kekahi aʻo kanaka, 40% hiki i RCT a 5% loaʻa ka ʻae hoʻoponopono. Holoholona unuhi holoholona-a-kanaka. ʻikepili pae pae: Kekahi aʻo kanaka 50; RCT 40; Apono hooponopono 5. Source: Ineichen et al., PLoS Biology 2024-06-13. Holoholona unuhi holoholona-a-kanaka Kekahi aʻo kanaka 50 RCT 40 Hooponoponoʻae ʻia 5 Puna: Ineichen et al., PLoS Biology (2024-06-13)

ʻO ka 5% ʻoi aku ka maikaʻi o ka heluhelu ʻana i ke kiʻi apono e kūʻē i kēlā asymmetry. Ua loaʻa i ka PLoS Biology analysis nā lāʻau lapaʻau maʻi maʻi 1% ʻae ʻia a me nā pilikia olakino ma 0%, kūʻē 15% no nā maʻi musculoskeletal a 20% no ke kanesa (Ineichen et al., PLoS Biology, 2024). Hoʻomaopopo nā mea kākau iā lākou iho e kuhikuhi ana ka helu haʻahaʻa haʻahaʻa i ka hoʻolālā ʻana i nā hemahema i nā haʻawina holoholona ʻelua a me nā hoʻokolohua lapaʻau mua, a i ʻoi aku ka nui o ka unuhi ʻana ma mua o ka mea i ʻōlelo nui ʻia. A 2026 ka nānā ʻana i ka loaʻa ʻana o ia helu i nā palapala i helu nui ʻia a hoʻopaʻapaʻa ʻia ma mua o ka hōʻoia kūʻokoʻa.

Hoʻohui ʻia nā kumukūʻai ʻae ʻia, lāʻau lapaʻau, nā mana hana a me nā pāʻoihana. ʻAʻole haʻahaʻa haʻahaʻa haʻahaʻa haʻahaʻa haʻahaʻa haʻahaʻa haʻahaʻa haʻahaʻa holoholona-a-kanaka a i ʻole ka pākēneka toxicity-concordance e hōʻike kūʻokoʻa ana he ʻoi aku ka maikaʻi o ka hoʻāʻo ʻana o ke kanaka-cell.. E hōʻoia i ke kumu hoʻohālike hou no kona wahi hope a me ka pōʻaiapili o ka hoʻohana.

He aha ka mea e kūpono ai ka Peptide Reagent no kahi kumu hoʻohālike e pili ana i ke kanaka

Ua kūpono kahi peptide reagent no kahi kumu hoʻohālike e pili ana i ke kanaka ke hōʻike ʻia nā ʻano ʻelima a hōʻoia kūʻokoʻa.: ʻike ʻike, hoʻomaʻemaʻe kemika a me ka ʻike haumia, maʻiʻo, ʻano hoʻohālikelike a me ka paʻakai, a me ka mana a i ʻole ke ana hana e pili ana i ka hoʻāʻo. ʻO kēia kiʻi ʻelima-ʻano ka mea hana kikoʻī a ke koena o kēia alakaʻi i kūkulu ai, a aia ia no ka loaʻa ʻole o nā peptides noiʻi-hoʻohana-wale i ka peptide-specific premarket koi ʻae i ka US a i ʻole EU.. ʻAʻole hoʻonohonoho ʻia ka maʻemaʻe liʻiliʻi loa o ka "hoʻohana noiʻi wale"., ʻike ʻike, sterility, endotoxin a i ʻole ke kūlana mana, no laila ke kau nei ka mea hoʻohana i ka kikoʻī (ʻO ka loiloi Springer o ka hoʻoponopono hoʻomohala lāʻau peptide, 2026). Ua hōʻoia ʻia kēlā kumu ma kēia loiloi, no laila e mālama i ka hoʻoponopono hoʻoponopono e like me ka pololei a hōʻoia i kāu ala hoʻoili.

Pono nā ʻano hiʻohiʻona like ʻole e hōʻike i ka hana analytical. Hiki ke kākoʻo i hoʻokahi paepae analytical i nā kumu he nui inā hōʻoia ʻia kēlā me kēia; ʻAʻole i hoʻokumu ʻia ka ʻike a i ʻole ka maʻiʻo ʻokoʻa ka hopena o ka wahi kiʻekiʻe. I Q2(R2) ua aponoia i ka malama o Novemaba 2023, me nā lā hoʻokō kūloko i hoʻoholo ʻokoʻa ʻia.

A laila hoʻohui ka ʻano hoʻohālike i nā kaohi i ka kikoʻī e komo. ʻO ka hana organoid a me ka organ-on-chip e hilinaʻi pinepine i nā matrices i loaʻa i ka holoholona-tissue.: ʻO kahi loiloi o nā hōʻike ʻē aʻe ʻo Matrigel synthetic e loaʻa mai ana ʻo Matrigel mai ka sarcoma ʻiole me ka hoʻohui molecular undefined a me nā hiʻohiʻona mechanical maikaʻi ʻole., a ʻaʻole hiki ke ʻike ʻia nā mea ulu i nā pae helu i kekahi mau pūʻulu i ʻehā mau pūʻulu kūʻokoʻa i hoʻāʻo ʻia ma hope. (Nā mea ʻokoʻa ʻē aʻe i ka Matrigel, 2020). ʻO kahi kikoʻī peptide i kākau ʻia no kahi 2D monolayer assay ʻaʻole e hoʻololi ʻokoʻa i kahi ʻano 3D i hoʻopili ʻia ma ka matrix., ʻo ia ke kumu e mālama ai nā pauku e pili ana i ke kaʻina hana, ka maemae, lepili a me ke kūpaʻa ma ke ʻano he laina kikoʻī kaʻawale ma mua o hoʻokahi helu maʻemaʻe.

Pehea e hāʻule ai ka Sequence Fidelity a me ka mea e hana ai kēlā me kēia hāʻule i kahi hōʻike

Hāʻule ka ʻoiaʻiʻo o ke kaʻina ma nā ʻano ʻokoʻa ʻelua, a he mau hopena like ʻole ko lākou no ka hoʻāʻo ʻana. Hoʻokumu ʻia nā kaʻina holoi i ka wā paʻa-phase synthesis ke pau ʻole ka pale ʻana o Fmoc a i ʻole ka hoʻopili ʻana., no laila ke hoʻomau nei ke kaulahao me ke koena ʻole; hana ʻia nā ʻoki ʻana i ka wā e paʻa mau ai ke kaulahao a pau ka ulu ʻana. ʻAʻohe hana a hapa ʻole nā ​​ʻano mea holoi, ka mea e hoʻoheheʻe i ka nui o ka ikaika maoli, a i ʻole hiki iā lākou ke hana ma ke ʻano he mea kūʻē kūʻē (MOL Hoʻololi i ka peptide microheterogeneity framework, 2026). No ka mea hoʻopuka ponoʻī kēlā papa hana, ʻaʻole kahi maʻamau i paʻi ʻia, a ua ʻōlelo ʻia ma ʻaneʻi no ka mīkini.

Hoʻololi ʻia ka nui o ka holoi ʻana i ke koena i nalowale. Kaʻana like ʻo Leu lāua ʻo Ile i ke koena monoisotopic 113.08406 A. Lys a me Gln aole: Kokoke ko lakou koena lehulehu 128.09496 a 128.05858 A, pakahi, a 0.03638 Da ʻokoʻa. ʻO ka hoʻoholo ʻana o kahi mea hana i kēlā ʻokoʻa e pili ana i ke kūlana o ka uku, hoʻoholo mana a me ka hana ʻano hana. E nana ʻo ke aʻo mua ʻana o ka mass-spectrometry.

Holoi

ʻĀpana nui

Palapala ʻike

ʻO Gly

-57.02 Da

Hoʻopili pū nā holoi polar liʻiliʻi; LC-MS pono

Ala

-71.04 Da

Hoʻoholo i ka hapa nui o nā ʻanuʻu hoʻohuli

S Kūʻai nui ʻo Peptide S ʻo ia

-87.03 Da

Pilikia co-elution me ka piko kiʻekiʻe

ʻO Val

-99.07 Da

ʻIke ʻia Aio Peptides na LC-MS

Leu / Me

-113.08 Da

ʻAlua Isobaric; ʻAʻole hiki ke hoʻokaʻawale ʻia e ka lehulehu wale

Lys / ʻO Gln

Lys: −128.09496 Da; ʻO Gln: -128.05858 Da

Kokoke-isobaric, ʻaʻole like nā nui kikoʻī; pili ka hoʻonā ʻana

ʻO nā Epimers ka hihia paʻakikī. Hana ʻia ka lāhui i ka D-amino-acid epimers i ka wā o ka hoʻoulu ʻana a me ka hui pū ʻana o ka amino-acid a ʻoi aku ka maʻamau ma cysteine ​​a me histidine.; kaʻana like nā epimers i ka molecular mass a me ka paʻa pinepine like, ʻo ia ka mea e hoʻokaʻawale ai iā lākou i waena o nā mea haumia paʻakikī (CertikLabs, 2026). A 2026 ʻO ka hiʻohiʻona analytical-chemistry ma ka peptide analysis ka mea maʻamau: nā ʻano like ʻole, deamidation, oxidation, Hiki ke hui pū nā ʻano acylation a me nā epimer, hoʻoholo hapa a noho paha ma lalo o ka piko nui, a hiki i ka ho'ā'o mua ke helu iā lākou me ka'ike'ole'ia (ʻO ka ʻepekema Analytical, 2026).

Kahi e kū ai ka hōʻike: ʻAʻohe kumu i loko o kēia loiloi e hoʻohālikelike i ka hoʻololi ʻana i ka mana i hana ʻia e kahi haumia ʻoki a i ʻole epimeric. Kākoʻo ʻia ka mīkini a me nā pūlima nui; ʻAʻole ka helu "epimers e ho'ēmi i ka mana e X%"., a ʻaʻole pono e hōʻike ʻia ma kahi kumu kumu.

No ke aha i hiki ʻole ai i kahi pākēneka maʻemaʻe ke wehewehe i kahi Peptide

ʻAʻole hiki i hoʻokahi pākēneka maʻemaʻe ke wehewehe i kahi peptide no ka mea ʻo ka hoʻomaʻemaʻe HPLC kahi ratio wahi, ʻaʻole he hakina nui. ʻO ka hoʻomaʻemaʻe HPLC ka ratio o ka wahi kiʻekiʻe i ʻike ʻia, a he peptide hiki ke kuai ma 97% ʻO ka maʻemaʻe HPLC ʻoiai ʻoi aku ka haʻahaʻa o ka waihona peptide net. Hāʻawi ka haʻihaʻi ʻana o ka mea hoʻolako i ka hana hoʻohālike peptide i ka helu helu: 10 mg i haawiia ma 97% HPLC maemae me 40% peptide ma o ka amino-acid analysis yield 3.88 mg o ka peptide pahuhopu maoli (waihona ʻenehana GenScript, lā ʻole, kiʻi ʻia 2026). ʻO ia kahi 61% pōkole ma waena o ka helu ma ka palapala hōʻoia a me ka helu i loko o ka paipu.

ʻO ka hoʻouka kaua ʻana he hapa nui o ke āpau. Hōʻike ka waihona ʻenehana like i ka maʻiʻo counterion, trifluoroacetate maʻamau, holo mau 10% i 30% o ka nui peptide i hāʻawi ʻia ma muli o ka helu koena kumu, me kahi laʻana hana o a 1,500 Da peptide e lawe ana i eha TFA adds ma 23.3% TFA ma ka nuipa (GenScript, lā ʻole). Lawe ka wai a me ke koena mea hoʻoheheʻe i kekahi hapa o ke koena. ʻAʻohe o kēia mau mea haumia i ke ʻano synthetic; he nui lākou ʻaʻole peptide.

ʻO ke alakaʻi ʻana i ka maʻemaʻe o ka mea hoʻolako ma o nā palapala palapala palapala hoʻomaʻemaʻe HPLC liʻiliʻi i ka hoʻohana ʻana: maluna 75% no ka ELISA a me ka peptide arrays, maluna 85% no ka bioassays in-vitro a me ka palapala ʻāina epitope, maluna 95% no ka hoʻopili ʻana i ka receptor-ligand quantitative a me ka quantitative proteolysis, a maluna 98% no ka crystallography, SAR a me nā mea lapaʻau (Manaʻo ʻo GenScript i nā alakaʻi maʻemaʻe, lā ʻole). ʻO kēia ka palapala palapala noi mea kūʻai, ʻaʻole he koi ICH a i ʻole USP, a pono e heluhelu pū ʻia me ka helu helu ma mua o ia. A quantitative receptor-ligand assay i hoakakaia ma 95% Maʻemaʻe HPLC akā hāʻawi ʻia ma 40% Ke holo nei ka ʻike ma kahi kokoke 38% o ka nui molar i manaʻo ʻia ke ʻole ke hoʻohana ʻia ka helu maʻiʻo e hoʻoponopono i ke kaupaona ʻana.

ʻO ka hopena kikoʻī he koi ʻelua laina: hōʻike i ka maʻemaʻe o ka HPLC a hōʻike i ka ʻike ma o ka nānā ʻana i ka waikawa amino a i ʻole ka hoʻoholo nitrogen, a laila e haʻi i ka helu e hoʻohana ai ka protocol assay no ka molarity. A 2026 ʻO ka hiʻohiʻona analytical ke hoʻopaʻapaʻa like mai ka ʻaoʻao ʻē aʻe, me ka ʻike ʻana ʻaʻole lawa ka waiwai maʻemaʻe RP-HPLC hoʻokahi me ka nui paʻa no ka mea hiki i nā ʻano microheterogeneous ke isobaric a pili pili paha. (ʻO ka ʻepekema Analytical, 2026).

Pehea e hoʻololi ai nā Koho Lepili i nā Heluhelu ma 3D a me Microfluidic Formats

Hoʻololi nā koho lepili i ka heluhelu ʻana ma nā ʻano 3D a me ka microfluidic no ka mea ua hoʻololi ka lepili i nā waiwai physicochemical e hoʻokele ana i ka hoʻopaʻa ʻana a me ka pilina o nā mea hana.. ʻO nā lepili fluorescent ka mea hana maʻamau no ke kiʻi, kahe cytometry, nā hoʻopaʻa hoʻopaʻa ʻana a me ka ʻimi kelepona, a he a 2024 ʻO ka hoʻohālikelike protocol no ka paʻa ʻana o ka peptide i ʻike ʻia e pili ana ka hoʻolālā lepili ponoʻī i ka degradation ana: Ua loiloi ka haʻawina i ka hana o ka hōʻailona fluorescent i ka paʻa o ka peptide a hoʻohālikelike i nā hopena e pili ana i nā peptides isotopically labeled., e kaha ana i ka pono o kela a me keia o na ala elua (Kohler et al., ka hoʻohālikelike o nā protocols e hoʻāʻo i ka paʻa o ka peptide i ke koko, 2024). Inā hoʻololi ka lepili i ke ana, ʻO ke degere o ka hōʻailona ʻana he ʻāpana kikoʻī, ʻaʻole he footnote catalog.

<papa helu ="blog-chart" kaila="laula-nui:640px;palena palena:1.5rem auto;nui-momona:12px;kiʻekiʻe laina:1.3;kala kala:hooilina"> <svg viewBox="0 0 560 380" kaila="laula-nui: 100%; kiekie: kaʻa; font-ohana: 'Inter', ʻōnaehana-ui, sans-serif; kala kala: #1e293b; --pakuhi-muted: #64748b;" kuleana="img" aria-labelledby="24-h-recovery-pdms-vs-coc-title 24-h-recovery-pdms-vs-coc-desc"> <kaila> /* Hoʻokomo ka mea hāʻawi i ka pakuhi i loko o kahi iframe nona ka ʻeleʻele ʻeleʻele, a he ʻano ʻokoʻa ka iframe i ka pakuhi, no laila ua hōʻike ʻia nā pahu pahu leka me he mau papa ʻeleʻele a puni (prod 09-22). Akaka ka palapala i loko o ka iframe ma ka paʻamau; ʻO ka pena kiʻi ma ʻaneʻi e uhi ana i ke kāʻei o ka element, a ke kau ʻia ka pakuhi, ʻaʻohe mea pili kēia. E mālama i nā pale kihi ma waho o kēia poloka: ʻO kahi mea ʻano i loko o kahi SVG i hoʻokaʻawale ʻia ma ke ʻano he ʻike haole, no laila, hoʻolei kekahi bracket hele i kēlā me kēia lula i loko. */ html, kino { hope: #ffffff; palena palena: 0; } @media (makemake-hoemi-holo: hoemi) { * { hoʻouluulu: ʻaʻohe !mea nui; hoʻololi: ʻaʻohe !mea nui; } } </kaila> <pololei x="0" y="0" laula="560" kiekie="380" rx="8" hoʻopiha="#ffffff" /> <inoa id="24-h-recovery-pdms-vs-coc-title">24 h Hoola hou: PDMS vs COC</inoa> <wehewehe id="24-h-recovery-pdms-vs-coc-desc">h Hoola hou: PDMS vs COC, e like me ka manao mai ke kumu i oleloia. 24 h Hoola hou: PDMS vs COC. ʻikepili pā hui: Primidone: PDMS 83.8, COC 86.8; ʻO Amlodipine: PDMS 2.8, COC 18.1; Loperamide: PDMS 5.3, COC 50.8.Kumu: Nā Mea Hana ACS & Nā Interface 2021-09-16.</wehewehe> <kikokikona x="280.0" y="29" heleuma kikokikona="waena" font-size="18" font-kaumaha="800" hoʻopiha="kala kala">24 h Hoola hou: PDMS vs COC</kikokikona> <laina x1="72" y1="277.0" x2="492" y2="277.0" hahau ="kala kala" opacity="0.08" /> <laina x1="72" y1="230.8" x2="492" y2="230.8" hahau ="kala kala" opacity="0.08" /> <laina x1="72" y1="184.5" x2="492" y2="184.5" hahau ="kala kala" opacity="0.08" /> <laina x1="72" y1="138.2" x2="492" y2="138.2" hahau ="kala kala" opacity="0.08" /> <laina x1="72" y1="92.0" x2="492" y2="92.0" hahau ="kala kala" opacity="0.08" /> <kikokikona x="66" y="281.0" heleuma kikokikona="hopena" font-size="10" hoʻopiha="kala kala" opacity="0.7">0</kikokikona> <kikokikona x="66" y="234.8" heleuma kikokikona="hopena" font-size="10" hoʻopiha="kala kala" opacity="0.7">25</kikokikona> <kikokikona x="66" y="188.5" heleuma kikokikona="hopena" font-size="10" hoʻopiha="kala kala" opacity="0.7">50</kikokikona> <kikokikona x="66" y="142.2" heleuma kikokikona="hopena" font-size="10" hoʻopiha="kala kala" opacity="0.7">75</kikokikona> <kikokikona x="66" y="96.0" heleuma kikokikona="hopena" font-size="10" hoʻopiha="kala kala" opacity="0.7">100</kikokikona> <pololei x="72.0" y="62" laula="10" kiekie="10" hoʻopiha="#f97316" /> <kikokikona x="87.0" y="71" font-size="11" hoʻopiha="kala kala">PDMS</kikokikona> <pololei x="133.8" y="62" laula="10" kiekie="10" hoʻopiha="#38bdf8" /> <kikokikona x="148.8" y="71" font-size="11" hoʻopiha="kala kala">COC</kikokikona> <pololei x="124.0" y="122.0" laula="16.0" kiekie="155.0" hoʻopiha="#f97316" /> <kikokikona x="132.0" y="118.0" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">83.8</kikokikona> <pololei x="142.0" y="116.4" laula="16.0" kiekie="160.6" hoʻopiha="#38bdf8" /> <kikokikona x="150.0" y="112.4" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">86.8</kikokikona> <kikokikona x="142.0" y="295.0" heleuma kikokikona="waena" font-size="10" hoʻopiha="kala kala" opacity="0.8"><puna x="142.0" dy="0">Primidone</tspan></kikokikona> <pololei x="264.0" y="271.8" laula="16.0" kiekie="5.2" hoʻopiha="#f97316" /> <kikokikona x="272.0" y="267.8" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">2.8</kikokikona> <pololei x="282.0" y="243.5" laula="16.0" kiekie="33.5" hoʻopiha="#38bdf8" /> <kikokikona x="290.0" y="239.5" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">18.1</kikokikona> <kikokikona x="282.0" y="295.0" heleuma kikokikona="waena" font-size="10" hoʻopiha="kala kala" opacity="0.8"><puna x="282.0" dy="0">ʻO Amlodipine</tspan></kikokikona> <pololei x="404.0" y="267.2" laula="16.0" kiekie="9.8" hoʻopiha="#f97316" /> <kikokikona x="412.0" y="263.2" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">5.3</kikokikona> <pololei x="422.0" y="183.0" laula="16.0" kiekie="94.0" hoʻopiha="#38bdf8" /> <kikokikona x="430.0" y="179.0" heleuma kikokikona="waena" font-size="9" hoʻopiha="kala kala">50.8</kikokikona> <kikokikona x="422.0" y="295.0" heleuma kikokikona="waena" font-size="10" hoʻopiha="kala kala" opacity="0.8"><puna x="422.0" dy="0">Loperamide</tspan></kikokikona> <kikokikona x="280.0" y="366" heleuma kikokikona="waena" font-size="10" hoʻopiha="kā mākou(--pakuhi-muted, kala kala)">Puna: Nā Mea Hana ACS & Nā mea hoʻohana (2021-09-16)</kikokikona> </svg> </huahelu>

ʻO ka mea hana ka mea hoʻololi ʻelua. A 2021 Nā Mea Hana ACS & Ua ana ka haʻawina sorption i ka hoʻihoʻi ʻana ma hope 24 hola o ka incubation static ma 37 °C mai a 100 µM ka hoʻomaka ʻana a loaʻa nā ʻokoʻa pili pono i nā mea: Ua loaa ka amlodipine ma 2.8% mai PDMS kū'ē 18.1% mai ka cyclic olefin copolymer, loperamide ma 5.3% kūʻē 50.8%, a me ka primidone ma 83.8% kūʻē 86.8%, me ka caffeine e hōʻike ana ʻaʻole ʻokoʻa nui (ʻO ka hui ʻana o Neuropsychopharmac ma nā mea Microfluidic, 2021). ʻO nā mea hoʻohui i hoʻāʻo ʻia he mau molekole liʻiliʻi a me nā mea pena, ʻaʻole nā ​​peptides, no laila, mechanistic ka hoʻoili: pili ka nui i ka lipophilicity pono'ī o ka peptide a ma ka ratio surface-to-volume o ka mea..

Hāʻawi kahi Lab on a Chip i ka nalowale o ka lāʻau i nā lako chip i nā levers hoʻolālā. Hiki ke lilo i PDMS ma mua 50% no nā pūhui hydrophobic: Cy3 NHS ester ma logPe 7.2 lilo oi aku mamua o 50%, Ua lilo ka rhodamine B ma mua o 50% ma logPe 5.7 a oi aku 25% ma logPe 6.7, oiai ua emi iho ka paclitaxel 5%, a ʻo ka hāʻawi ʻana mai o ka paipu ma lalo o 7% o ka huina poho (Lab ma kahi Chip, 2017). Hōʻike ka haʻawina like i ka hoʻonui ʻana i ka helu Péclet, ma ka hoʻokiʻekiʻe ʻana a i ʻole ka hoʻohaʻahaʻa ʻana i ka nui o ke kahawai, hiki ke mālama i ka poho ma lalo 5% ʻoiai ma nā ʻāpana ʻāpana kiʻekiʻe. ʻO ka hopena kikoʻī he hui like: e haʻi i ke kiʻekiʻe o ka hoʻopaʻa inoa ʻana a me ke ana ʻana a me ka hoʻihoʻi ʻana o ke kūkulu ʻia, a hoʻopaʻa pono i ka mea hana a me ke ʻano kahe e kūʻē i kahi peptide ʻelele ma mua o ka hana ʻana i kahi maʻi.

Pehea e ana i ke kūpaʻa ʻana o ka Peptide ma ka Matrix Model maoli

Pono e ana ʻia ka paʻa o ka peptide ma ka matrix kŘkohu maoli no ka mea, pili ka matrix i ka helu degradation, a ua lawa ka laha e hoʻololi i ka hopena haʻawina. A 2024 ka hoʻohālikelike protocol ana i ka peptide hapalua-ola i loko o ke kanaka koko plasma diluted 1:1 me DPBS ma 10 µM a 37 °C: hoʻokahi 36-koena ghrelin analogue i hāʻawi 50.5 h (95% CI 39.8–66.7 h), ʻoiai ua hōʻike ʻia kahi analogue e pili ana i kahi hoʻohaʻahaʻa ma luna o ka pukaaniani 72-hola like (Kohler et al., 2024). ʻEhiku peptides o 9 i 36 ua hoʻāʻo ʻia nā koena. Ua ʻike ʻia ka noiʻi like ʻana ua hāʻawi ka peptide like i ka hapalua o nā ola a hiki i ʻelua manawa ma waena o nā pūʻulu plasma mai nā mea hāʻawi like ʻole., a ʻoi aku ka kiʻekiʻe o ke kūpaʻa i ka HEK-293 supernatant ma mua o ka plasma no ʻekolu o ʻehā peptides, me hoʻokahi peptide e neʻe ana mai 3.2 h i ka plasma i 23.3 h i ka HEK-293 supernatant. Hgh A i ʻole Peptides

E wehewehe i ka hoʻomākaukau laʻana a loiloi i ka hoʻihoʻi ʻana, nā hopena matrix a me nā poho pili i ka manawa. ʻAʻole hoʻopau ʻokoʻa ka hoʻihoʻi piha ʻana i kahi hōʻike kūpaʻa inā ʻike ʻia ia, kūpono kūpono a helu ʻia me nā mana kūpono. Hiki ke kuhi hewa ʻia ka hoʻihoʻi ʻana i nā loli i hoʻoponopono ʻole ʻia.

No nā ʻano 3D a me ka matrix-embedded formats, ʻoi aku ka lahilahi o ka waihona hōʻike a pono e mālama ʻia e like me ia. ʻAʻohe haʻawina i loko o kēia loiloi e hōʻike ana i ke ana ʻana o ka peptide degradation half-life i loko o ka moʻomeheu organoid a i ʻole ma kahi matrix 3D i loko o ka serum me nā kūlana like me ka hana plasma.. No laila, ʻo ka ʻōlelo kikoʻī e pono ai ke ʻano ma mua o ka helu: wehewehe i ka matrix, ka wela, ka hoʻomaka ʻana, ka puka aniani hōʻike a me ke ʻano ʻike, a laila e ana i ka hapalua o ke ola ma ia matrix ma mua o ka hoʻomaka ʻana o ke aʻo ʻana. I Q5C, ke alakaʻi kūpaʻa no nā huahana olaola, pili 'ane'i no kona pa'i 'ana ma mua o kona laulā: ua ʻōlelo ʻo ia nā huahana nona nā mea hana maʻamau he mau protein a i ʻole polypeptides "ʻano koʻikoʻi i nā mea kūlohelohe e like me ka hoʻololi ʻana o ka mahana., oxidation, māmā, ionic content, a ʻako,” a ʻo ka mālama ʻana i ka conformation a me ka hana e pili ana i nā ikaika non-covalent a me nā covalent (I Q5C, 1996, ʻike i kēia manawa 2018). ʻAʻole ʻo Q5C kahi peptide-reagent-specific, ʻaʻole pono e haʻi ʻia me he mea lā.

Hoʻohana ka mālama mālama ʻana i ka laina kikoʻī like. ʻO ke alakaʻi no ka mālama ʻana i ka mea kūʻai aku, ʻo ka peptide i hoʻohui ʻia i loko o ka wai bacteriostatic ma 2-8 °C e paʻa mau i ka pono no 28 i 90 lā, pono e hoʻohana ʻia ka peptide i loko o ka wai sterile me ka mālama ʻole 24 hola, ʻoi aku ka pālua o kēlā me kēia 10 °C piʻi, a ʻo kēlā hoʻohana hoʻokahi aliquoting ʻo ia ka hoʻohaʻahaʻa maʻamau no ka hoʻohui ʻana i ka freeze-thaw (ʻO ka protocol mālama mālama ʻo Peptra Labs, 2026). He alakaʻi alakaʻi kēia, ʻaʻole kahi haʻawina kūpaʻa i ana ʻia, a pono e hōʻoia ʻia e pili ana i kāu ʻikepili matrix ponoʻī ma mua o ka lawe ʻia ʻana ma ke ʻano he kumu hoʻokuʻu.

He aha ka mea e pono ai ka mea nānā i loko o kahi pūʻulu ʻikepili Peptide

Pono ka mea loiloi i kahi pūʻolo ʻikepili kahi e hana hou ʻia ai ka haʻawina, ʻaʻole ka palapala hōʻoia o ka ʻimi wale ʻana. ʻO ke alakaʻi pololei ʻikepili o ka MHRA e wehewehe i ka maʻamau: ALCOA (Hiki ke pili, Legible, ʻO kēia manawa, Kumu, pololei) hoʻohui piha, Kūlike, Hoʻomau a Loaʻa, me ka ʻokoʻa ʻole o nā manaʻo i hoʻohana ʻia ka acronym, a ua ʻōlelo ʻia e ʻae ka ʻikepili maka i ke kūkulu hou ʻana i nā hana a ʻo ka metadata he ʻāpana koʻikoʻi o ka moʻolelo kumu. (MHRA GXP Ke alakaʻi a me ka wehewehe pono ʻana i ka ʻikepili, Hoʻoponopono 1, Malaki 2018). He hoʻolālā GXP maʻamau kēia, ʻaʻole he mea kikoʻī NAM, a hiki ke ʻōlelo ʻia ʻo ia wale nō ka maʻamau e pono ai e hui ʻia nā waihona.

Hoʻopili ʻia i kahi reagent peptide, ʻO kēlā maʻamau e hoʻopuka i kahi papa inoa kahua. Pono ka ʻike i ka hōʻoia ʻana o ka nuipa a me ka pae kaʻina, maikaʻi loa LC-MS/MS a i ʻole ka palapala peptide, no ka mea, ʻaʻole hiki i ka nuipa paʻa ke hoʻokaʻawale i nā holoi isobaric a i ʻole epimer (ʻO ka ʻepekema Analytical, 2026). Pono ka hoʻomaʻemaʻe kemika i ka chromatogram, ʻaʻole wale ka pākēneka, no laila hiki i ka mea loiloi ke ʻike i kahi e noho ai nā piko pili i ka piko nui. Pono ka ʻike i ka nānā ʻana i ka amino-acid a i ʻole ka hoʻoholo nitrogen me ke ʻano i kapa ʻia. Pono ke ʻano counterterion a me ka paʻakai i ka waiwai i haʻi ʻia, haawiia ka 10% i 30% ka laulā nui maʻamau no TFA (GenScript, lā ʻole). Pono ʻo Potency i kahi hoʻokolohua e pili ana i ka heluhelu i manaʻo ʻia.

kahua pūʻolo

He aha ka mea e pono ai

No ke aha e pono ai ka mea loiloi

ʻIkepili

Nuipa paʻa me LC-MS/MS a i ʻole ka palapala ʻāina peptide

ʻAʻole nalo ka nuipa paʻa i ka holoi ʻana isobaric a me nā epimer Mea Hana Polypeptide

Maemae

ʻO Chromatogram me ka hui pū ʻana, ke ʻano a me ka gradient

ʻAʻole hiki ke loiloi ʻia ka ʻāpana-% me ka ʻole o ka meheu

Maʻiʻo

Ka nānā ʻana i ka amino-acid a i ʻole ka hoʻoholo nitrogen, ʻano i kapa ʻia

Hoʻololi i ka ʻāpana-% i loko o ka nui molar hiki ke kaupaona ʻia

Kūʻē / ʻano paʻakai

Hoʻolaha ʻia ka counterion a me ka pākēneka o ka nuipa i hāʻawi ʻia

ʻO ka TFA maʻamau he 10–30% o ka nuipaʻa

Ka mana

ʻIke pili i ka heluhelu i manaʻo ʻia

E hōʻoia i ka hana o ka mea, ʻaʻole i kēia manawa wale nō

Paʻa

Matrix, mahana wela, hoʻopaʻa ʻana, puka aniani, ʻano hana

Nā uku pili matrix; ʻaʻohe hapalua ola paʻamau

Nā moʻolelo

Nā waihona ʻikepili maka, metadata, ala hoʻokolo, mau kope oiaio

Koi hana hou ʻia ʻo ALCOA+

Aia nā mea koho ʻelua ma ka papa inoa ke koi ʻia ke ʻano hoʻohālike. ʻAʻole hoʻonohonoho ʻia ka hoʻāʻo endotoxin a me nā palapala sterility e ke kūlana noiʻi-hoʻohana-wale, a ʻo kahi moʻomeheu 3D me kahi pale i hoʻopaʻapaʻa ʻia ʻoi aku ka maʻalahi i ka haumia ma mua o ka luawai 2D.. Pono e noi ʻia nā mea ʻelua ma mua o ka manaʻo. Pili ka loina like i ka hailona: no ka mea, ʻokoʻa ka ʻike a me ka counterion ma ka hailona, ʻO kahi kikoʻī e kūpono i hoʻokahi ʻāpana kūʻē i kahi maʻamau kuhikuhi a laila e ʻae i nā ʻāpana hope ma kahi palapala hōʻoia wale nō ʻaʻole ia he kikoʻī., he ana hookahi.

Kahi e kū ai ka ʻōlelo kikoʻī me ka pae

Ma mua o ke kauoha ʻana, wehewehe i ka ʻike haumia o ka assay, ka ʻike o ka hailona a me ke ʻano maʻiʻo. E helu i ka noʻonoʻo ʻana mai ke kumu maʻiʻo i hōʻike ʻia a pale i ka hoʻoponopono ʻelua inā ua ana ʻo ia i ka peptide target. E hōʻoia i ka hoʻihoʻi ʻana a me ka paʻa o ka mea hana me ka hoʻohana ʻana i ka hana maoli a me ka matrix; ʻAʻole nā ​​huaʻōlelo hoʻihoʻi peptide nā hopena sorption liʻiliʻi.

Loaʻa nā palena kūpono e haʻi aku i ka framework. ʻAʻole ia e pani i ka hōʻoia ʻokoʻa-o-hoʻohana, a ʻaʻohe kumu i loko o kēia loiloi i kapa ʻia kahi NAM i hōʻoia ʻia i hōʻike ʻole i ka haʻahaʻa i ka hoʻāʻo holoholona no kahi pōʻaiapili o ka hoʻohana.. ʻAʻole ia e hoʻonā i ka nīnau epimer potency, no ka mea, ʻaʻole i ʻike ʻia kahi helu hiki ke hoʻololi no kahi haumia epimeric. ʻAʻole ia e hāʻawi i kahi hōʻailona hoʻololi like ʻole o ka lot-to-lot matrix a i ʻole ka pākēneka adsorption kikoʻī peptide., ʻAʻole i helu ʻia nā mea ʻelua i nā kumu i loiloi ʻia. A ʻaʻole ia e pane i ka nīnau hoʻoponopono inā e ʻae ʻia kahi ʻikepili NAM i hāʻawi ʻia, no ka mea, ʻaʻohe kumu e hōʻike i ka nui o nā hoʻouna IND e pili ana i ka NAM i ʻae ʻia a i ʻole ka nui o nā paʻa lapaʻau i hoʻopuka ʻia ma ka ʻikepili NAM.

ʻO kāna mea e hāʻawi ai he kikoʻī hiki ke kākau ʻia, hōʻoia a kūkulu hou ʻia. ʻO nā ʻano ʻelima (ʻike ʻike, ʻano maʻemaʻe a me ka haumia, maʻiʻo, ʻano hoʻohālikelike a me ka paʻakai, ikaika) kēlā me kēia palapala ʻāina i kahi kaʻina hana analytical inoa ma lalo o ICH Q2(R2) (I Q2(R2), 2023), a hoʻopuka kēlā me kēia i kahi moʻolelo e hoʻokō i ka maʻamau MHRA hana hou (MHRA, 2018). ʻO ka hana aʻe, ʻo ka lawe ʻana i ka pākaukau ma luna i kāu mea hoʻolako o kēia manawa a nīnau i nā māla i loaʻa, e koi ana i ke kauoha hoololi, a na kāu paipu QC pono'ī e hana. ʻO ka loiloi kikoʻī e pili ana i kahi kaʻina kikoʻī ke ala wikiwiki loa e ʻike ai i kahi e noho ai nā āpau.

Nīnau pinepine

Hiki a 98% ʻAʻole ʻae ʻia ka peptide maʻemaʻe HPLC i kahi assay?

ʻAe, a ʻo ka hāʻule maʻamau ʻaʻohe mea pili i ka piko nui. ʻO ka hoʻomaʻemaʻe e ka HPLC he lākiō ʻāpana i ana ʻia i hoʻokahi lōʻihi nalu; ʻaʻohe mea e pili ana i nā mea ʻē aʻe i loko o ka hue. Holoi i nā huahana e hui pū me ka pahuhopu, counterion koena, a me ka wai i hoʻopaʻa ʻia i nā mea a pau e hele pū me nā mea a pau i ke kaumaha. Ke kau ʻia kahi peptide e ke kaumaha nui me ka ʻole o ka hoʻoponopono ʻana i ka ʻupena, loaʻa i ka assay ka liʻiliʻi o ka molekele pahuhopu ma mua o ka manaʻo o ka protocol, a hiki ke hoʻololi ʻia ka mana a i ʻole ka pihi paʻa no ia kumu wale nō. Hoʻohana ʻia ka ʻokoʻa maʻemaʻe-versus-maʻiʻo ma ka ʻāpana maʻemaʻe ma luna.

ʻO ka maʻemaʻe o ka HPLC a me ka maʻi peptide net ke ana like?

ʻAʻole. Pane lākou i nā nīnau like ʻole. Hōʻike ka hoʻomaʻemaʻe HPLC i ka hapa o nā mea e hoʻopaʻa ai i ka UV i ka piko i hoʻopaʻa ʻia e pili ana i nā mea āpau ma ka chromatogram.. Hōʻike ka ʻikepili peptide Net i ka nui o ka nui i hāʻawi ʻia he peptide maoli, ma hope o ka unuhi ʻana a me ka wai. Hiki ke nānā maikaʻi ʻia kahi laʻana ma ke ana mua a haʻahaʻa loa ma ka lua, ʻo ia ke kumu e pili pū ai nā helu ʻelua ma kahi kikoʻī ma mua o ke kū ʻana o kekahi i kekahi.

Pehea wau e haʻi ai i kahi ʻokiʻoki mai kahi epimer?

E hoʻomaka me ka nuipa. Hoʻopau ka ʻoki ʻana i nā koena, no laila, hoʻololi ka nuipaʻa ma kahi paʻa, ka nui hikiwawe no kēlā me kēia waikawa amino i nalowale, a e hōʻike ʻo LC-MS iā ia ma ke ʻano he ʻano ʻokoʻa ke ʻole ia e hui pū. Ua like ka nuipa o ka epimer me ka pahu hopu, no ka mea, ua paʻa ke kaʻina a ua loli wale ka stereochemistry ma kahi kikowaena. No laila ʻaʻole hiki ke hoʻoholo i ka spectrometry nui. ʻIke ʻia nā Epimers e ka hoʻokaʻawale chromatographic e kūʻē i kahi maʻamau kuhikuhi a i ʻole e nā ʻano chiral e like me ka optical rotation.. Hoʻopili ka ʻāpana sequence-fidelity ma luna i kēlā me kēia ʻano hana hemahema a me kāna hopena hoʻāʻo.

Manaʻo ke kūpaʻa ma ka buffer i ke kūpaʻa ʻana i ke ʻano organoid?

ʻAʻole. ʻO ka paʻa paʻa he kumu kūpono, akā, ʻaʻole ia e hoʻololi i kahi matrix paʻakikī. Loaʻa nā protease i loko o ka media organoid a me ka organ-on-chip media, nā ʻāpana serum a me nā hana i loaʻa i ka cell i nele i ka buffer, a hiki i ka peptide hoʻokahi ke hoʻohaʻahaʻa i nā kumukūʻai like ʻole ma waena o nā matrices. E ana i ka paʻa i loko o ka matrix e hoʻohana maoli ai ka assay, a hōʻike i ka matrix, mahana wela, ʻO ke ʻano o ka hoʻopaʻa ʻana a me ka ʻike ʻana ma ka ʻaoʻao o ka hapalua o ke ola i hiki ke unuhi ʻia ka helu.

He aha ka mea e pono ai i loko o kahi palapala hōʻoia no ka pale ʻana?

Ma ka liʻiliʻi: HPLC analytical me ka chromatogram, nuipa spectrometry hōʻoia i ka ʻike, a me ka nānā 'ana i ka amino-acid no ka nui. ʻO kēlā mau mea ʻekolu uhi maʻemaʻe, ʻike a me ka ʻike, ʻo ia nā ʻōlelo ʻekolu e hoʻāʻo ai ka mea loiloi. Kānāwai kūʻē, ka wai na Karl Fischer, ʻO ka hoʻāʻo ʻana o ka endotoxin a me ka hoʻololi ʻana o ka optical he mea hoʻohui koho e pono ai ke ʻike ʻia ka assay i ke ʻano paʻakai., osmolarity, endotoxin a i ʻole stereochemistry. Hōʻike ka ʻāpana ʻikepili-package ma luna i nā kahua i manaʻo ʻia e ka mea loiloi e ʻike.

Hoʻoponopono ʻia nā peptides noiʻi-hoʻohana wale?

ʻAʻole ma kahi koi premarket kikoʻī peptide. ʻO ka koho ʻana ʻo RUO e kau i ke kuleana no ka pono o ka mea kūʻai, 'o ia ho'i na 'oe ke kiko'ī e kākau a pale aku. ʻO ia ka hopena kūpono o ke alakaʻi holoʻokoʻa: papa maemae, ʻano kūʻē, lepili kemika, ʻO ka hoʻoponopono maʻiʻo a me ka hoʻāʻo paʻa ʻana nā koho āu e hana ai a palapala, ʻaʻole paʻa ke koi ʻia ka mea hoʻolako e hoʻolako.

Ua mākaukau nā ʻano ala hou e pani i ka hoʻāʻo holoholona?

Koe aku, a ua hoʻonohonoho ʻia ka manawa. Hoʻonohonoho ka palapala alanui a ka FDA a 3 i 5 ka pahuhopu makahiki o ka hana ʻana i nā haʻawina holoholona ma mua o ka mea maʻamau no ka palekana preclinical a me ka hoʻāʻo ʻana i nā mea make, me nā NAM i hoʻopaʻa ʻia e lawe ana i ka ukana i ka wā e oʻo ai (ʻO ke alanui FDA e hōʻemi i ka hoʻāʻo holoholona ma nā haʻawina palekana preclinical, ʻApelila 2025). He papa CDER i paʻi ʻia ma ʻOkakopa 2025 papa inoa i nā pōʻaiapili i hiki ke ʻae ʻia nā papahana nonclinical maʻalahi me nā NAM. Nīnau nā ʻōlelo hoʻohewa i paʻi ʻia no ka palapala alanui inā hiki i ka hōʻoia ʻana a me ka ʻoihana hoʻonaʻauao ke hoʻokō me kēlā papa hana. ʻO ka mea i hāʻawi ʻole ʻia e nā mea hōʻike he helu hoʻohana a i ʻole ka ʻikepili paʻa i ka lāʻau lapaʻau, no laila, ʻo ke kūlana ʻoiaʻiʻo, ua hoʻonohonoho ʻia ke kuhikuhi a ʻaʻole i hōʻoia ʻia ka wikiwiki. ʻO ka ʻāpana pili hoʻohālike ma luna e uhi i ka mea e hōʻike ʻia e ke kumu hoʻohālike pili kanaka ma mua o ka hiki ke lawe i kēlā kaumaha.

Ka hopena

He ʻoiaʻiʻo ka hoʻololi hoʻoponopono i nā kumu hoʻohālike pili kanaka, aka, o ka reproducibility o ia mau kŘkohu e kau ma luna o reagent 'ano i uhi ole ia i ka palapala o ka anaana. ʻO ka ʻōlelo kikoʻī ʻelima (ʻike ʻike, hoʻomaʻemaʻe kemika a me ka ʻike haumia, maʻiʻo, ʻano hoʻohālikelike a me ka paʻakai, ikaika) hāʻawi i kēlā me kēia ʻano i kāna kaʻina hana ponoʻī ma lalo o ICH Q2(R2), a hāʻawi ka papa ʻikepili-package field i kēlā me kēia kaʻina hana i kahi moʻolelo e hiki i ka mea loiloi ke kūkulu hou ma lalo o ka maʻamau MHRA ALCOA+. ʻO nā ʻano hana ʻole ʻekolu e hōʻike kūʻē i nā mea i hōʻike ʻia e nā hōʻike: he helu maʻemaʻe ʻaʻole he helu maʻiʻo, kahi holoi a i ʻole epimer e noho ana ma lalo o ka piko nui, a he matrix a mea paha e wehe i ka peptide ma mua o ka ʻike ʻana o nā cell.

He pōkole ka lula hoʻoholo. E hoʻokaʻawale i ka heluhelu ʻana, hoʻonohonoho i ka hoʻoponopono maʻiʻo, kūpono i ke ʻano, a ana i ka paʻa i ka matrix maoli. Kahi e kū ai ka hōʻike, e olelo pela: ʻaʻohe NAM i hōʻoia ʻia i hōʻike ʻia ʻaʻole i haʻahaʻa i ka hoʻāʻo holoholona no kahi pōʻaiapili i kapa ʻia, ʻaʻohe peptide-specific adsorption pākēneka i loaʻa no PDMS a i ʻole COC, ʻAʻole i ana ʻia ka hapalua o ke ola no kahi peptide i loko o ke ʻano organoid i loaʻa i kēia loiloi. ʻO kēlā mau āpau ke kumu e kākau ʻia ai ka kikoʻī e ka mea hoʻohana ma mua o ka hoʻoilina mai ka mea hoʻolako. E lawe i ka papaʻaina i kāu kaʻina aʻe a nīnau i nā kahua i loaʻa mua, ka mea e pono ai ke kauoha hoʻololi, a na kāu paipu QC pono'ī e hana.


Hōʻike: He hoihoi ko ka mea kākau i ka peptide synthesis a me nā lawelawe analytical. He ʻano kikoʻī kēia alakaʻi no ka loiloi reagent a ʻaʻole ia he protocol i hōʻoia ʻia a i ʻole he palapala hoʻouna hoʻoponopono..


Mea hoʻopuka: MOL Changes. Hoʻohou 15 ʻOkakopa 2026. Hoʻopili kēia ʻatikala i nā kumu lehulehu i ʻōlelo ʻia a hāʻawi i kahi hoʻolālā hoʻolālā. ʻAʻole ia e hōʻike i kahi loiloi hoʻolako kūʻokoʻa a i ʻole kahi noiʻi hoʻokolohua MOL Changes kumu.

Hōʻike kālepa: Hāʻawi ʻo MOL Changes i nā lawelawe peptide a loaʻa iā ia kahi hoihoi pāʻoihana i kēia kumuhana. Pono e hoʻopaʻa ʻia ka mana o ka papahana a me ka laulā analytical e kūʻē i ka hoʻohana i manaʻo ʻia a me kahi kikoʻī i kākau ʻia.

Zejun Peng

Zejun Peng

Luna ʻenehana Nui; ʻO ka mea akamai i ka peptide Synthesis Kaʻike kumu: ʻO ka peptide synthesis paʻakikī, nā hoʻololi ʻana o ka amino acid kūlohelohe, a me ke kūkulu ʻana i nā peptides cyclic a me nā peptides stapled.

moʻokalaleo:He ʻike nui ʻo Zejun Peng i ka kemika kūlohelohe a me ka synthesis peptide. Maikaʻi ʻo ia i ka hoʻohana ʻana o ka solid-phase peptide synthesis (SPSS) a me ka peptide synthesis wai (LPPS), a akamai loa i ka lanakila ʻana i nā "paʻakikī loa-e-synthesize sequences" (e like me nā peptides ultra-long-chain, nā kaʻina hydrophobic kiʻekiʻe, a me ka pelu ana i na mea paa disulfide lehulehu). Ma lalo o kāna alakaʻi, ua lanakila ka hui i nā bottlenecks ʻenehana i kekahi mau hoʻololi kūikawā (e like me ka N-methylation, PEGylation, a me ka lepili fluorescent), ka mālama ʻana i ka helu kūleʻa synthesis o luna 98%.

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana